[Retracted] Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma

Table 1

Comparison of baseline date in included patients.

	Original research drug group (n = 149)			Generic drug group (n = 120)
Median age	61			61			0.466
S	60.55  9.434			60.33  8.665
Gender
Male	88 (0.59)			66 (0.55)			0.503
Female	61 (0.41)			54 (0.46)
Basic disease species
No basic disease	35 (0.23)			15 (0.13)			0.068
1 basic disease	41 (0.28)			28 (0.23)
2 basic diseases	33 (0.22)			25 (0.21)
3 basic diseases	20 (0.13)			29 (0.24)
4 basic diseases	8 (0.05)			13 (0.11)
5 basic diseases	5 (0.03)			5 (0.04)
6 or more basic diseases	7 (0.05)			5 (0.04)
Disease staging	I	II	III	I	II	III
ISS	37 (0.25)	36 (0.24)	71 (0.48)	24 (0.20)	25 (0.21)	68 (0.57)	0.359
DS	5 (0.03)	16 (0.11)	125 (0.84)	5 (0.04)	14 (0.12)	98 (0.82)	0.902
R–ISS	14 (0.09)	58 (0.39)	29 (0.19)	13 (0.11)	51 (0.43)	28 (0.23)	0.435